Search

From garage start-up to global pharma: combining strengths to advance regenerative medicine

Article describing how a strategic partnership between Global Stem Cell and Boehringer Ingelheim Animal Health has played a key role in helping the companies accelerate breakthroughs in regenerative medicine.

Partnering for Innovation in Animal Health

Video with Erik Haaksma and Megan Grether describing how partnering is an essential component of innovation at Boehringer Ingelheim Animal Health.

Boehringer Ingelheim Fremont, Inc.

Fremont, California, is the home of Boehringer Ingelheim’s rapidly growing US Biopharmaceuticals Business Unit

Celebrating Innovation | Partnering

BI’s Innovation Prize was established in Boston in 2015 to recognize the challenge and dedication of entrepreneurs in advancing new ideas & science.

Confronting health disparities in clinical trials

As a research-driven pharmaceutical company, one of our priorities is to ensure there’s more representation from underserved communities, particularly for clinical cancer trials.

Boehringer Ingelheim Innovation Prize Video 2023

Video providing an overview of the Innovation Prize initiative and the benefits of participating and receiving the award.

Exploring beyond boundaries for innovation in animal health

Exploring beyond boundaries by partnering with human pharma and animal health may hold the key to accelerating innovation in animal health.

Translating Human Pharma Science into Animal Health Innovation

Megan Grether shares her perspectives on the importance of translating human pharma science to accelerate innovation in animal health

Boehringer Ingelheim caps patient out-of-pocket costs for its inhaler portfolio at $35 per month

Boehringer Ingelheim cap out-of-pocket costs at $35 per month for eligible patients for all of the company’s inhaler products.

First half of 2024: Boehringer Ingelheim progresses pipeline at pace and reaches major milestones

Innovating for our business

We drive innovation across our complex business landscape at Boehringer Ingelheim. Technology is an integral part of our core business processes and we focus on advanced technologies.

Thinking differently could eradicate some areas of retinal disease

Retinal disease could be eradicated by thinking differently. Degenerative eye conditions can be cured with a patient-first approach, says Dr Victor Chong.

Boehringer Ingelheim and Zealand Pharma Receive FDA Fast Track Designation for Investigational Treatment for NASH

First half of 2021: Boehringer Ingelheim makes fundamental progress in research and development

Boehringer Ingelheim Partners with Thoeris to Investigate a Novel Approach to Treat Urea Cycle Disorders

Disentangling Fibrosis: Finding ways to fix ‘repair gone wrong’

Partnering Purpose: BI Gives Back | Boehringer Ingelheim US

Hear from Sheila Denton, Senior Vice President, General Counsel and Corporate Secretary, on the importance of giving back to our communities.

Welcome to Innovation @ Boehringer Ingelheim

4 Possible Signs of Diabetes in Cats | Boehringer Ingelheim US

Click here to read more on the possible signs of diabetes in your feline friends, including how to identify and prevent potential symptoms and risks.

Boehringer Ingelheim Statement: Favorable Ruling on Humira® Patent Challenge from U.S. Patent and Trademark Office

AbbVie and Boehringer Ingelheim announce global collaboration on promising immunology compounds

Efficacy and safety maintained in patients who switched from Humira® to biosimilar Cyltezo®

FDA Expands Approval of SPIRIVA® RESPIMAT® (tiotropium bromide) Inhalation Spray for Maintenance Treatment of Asthma in Children

Internal Teat Sealant for Dairy Cows | Boehringer Ingelheim US

Boehringer Ingelheim adds internal teat sealant to their dairy mastitis portfolio, with a more ergonomic design and improved removal process.

Boehringer Ingelheim Pharmaceuticals, Inc.

About Us

Human Health

Animal Health

Science & Innovation

Partnering

Careers